Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
SCCL
MCID: SML038
MIFTS: 69

Small Cell Cancer of the Lung (SCCL)

Categories: Cancer diseases, Neuronal diseases, Rare diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Small Cell Cancer of the Lung

About this section

MalaCards integrated aliases for Small Cell Cancer of the Lung:

Name: Small Cell Cancer of the Lung 57
Small Cell Lung Cancer 73 20 58 36 54
Small Cell Lung Carcinoma 29 6 44 17
Lung Small Cell Carcinoma 12 20 15
Small-Cell Cancer of Lung 57 13
Sclc 57 58
Small Cell Neuroendocrine Carcinoma of the Lung 20
Small Cell Carcinoma of Lung 70
Cancer, Lung, Small Cell 39
Carcinoma, Small Cell 70
Oat Cell Lung Cancer 20
Sclc; Sccl 57
Sclc1 57
Sccl 57

Characteristics:

Orphanet epidemiological data:

58
small cell lung cancer
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Adult;

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
autosomal dominant


HPO:

31
small cell cancer of the lung:
Inheritance autosomal dominant inheritance


Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Respiratory diseases Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare respiratory diseases


External Ids:

Disease Ontology 12 DOID:5409
OMIM® 57 182280
KEGG 36 H00013
MeSH 44 D055752
NCIt 50 C4917
SNOMED-CT 67 254632001
ICD10 via Orphanet 33 C34.9
UMLS via Orphanet 71 C0149925
Orphanet 58 ORPHA70573
MedGen 41 C0149925
SNOMED-CT via HPO 68 126713003 263681008
UMLS 70 C0149925 C0262584
Sources

Summaries for Small Cell Cancer of the Lung

About this section
KEGG : 36 Lung cancer is a leading cause of cancer death among men and women in industrialized countries. Small cell lung carcinoma (SCLC) is a highly aggressive neoplasm, which accounts for approximately 25% of all lung cancer cases. Molecular mechanisms altered in SCLC include induced expression of oncogene, MYC, and loss of tumorsuppressor genes, such as p53, PTEN, RB, and FHIT. The overexpression of MYC proteins in SCLC is largely a result of gene amplification. Such overexpression leads to more rapid proliferation and loss of terminal differentiation. Mutation or deletion of p53 or PTEN can lead to more rapid proliferation and reduced apoptosis. The retinoblastoma gene RB1 encodes a nuclear phosphoprotein that helps to regulate cell-cycle progression. The fragile histidine triad gene FHIT encodes the enzyme diadenosine triphosphate hydrolase, which is thought to have an indirect role in proapoptosis and cell-cycle control.

MalaCards based summary : Small Cell Cancer of the Lung, also known as small cell lung cancer, is related to lung combined type small cell carcinoma and lung disease. An important gene associated with Small Cell Cancer of the Lung is RB1 (RB Transcriptional Corepressor 1), and among its related pathways/superpathways are Small cell lung cancer and MicroRNAs in cancer. The drugs Caffeine and Vinblastine have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and lymph node, and related phenotypes are neoplasm of the lung and nervous system

Disease Ontology : 12 A lung carcinoma that has material basis in primitive-appearing cells that are smaller than normal cells and is located in the lung.

Wikipedia : 73 Small-cell carcinoma is a type of highly malignant cancer that most commonly arises within the lung,... more...

More information from OMIM: 182280
Sources

Related Diseases for Small Cell Cancer of the Lung

About this section

Diseases in the Lung Large Cell Carcinoma family:

Small Cell Cancer of the Lung Lung Clear Cell Carcinoma

Diseases related to Small Cell Cancer of the Lung via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1323)
# Related Disease Score Top Affiliating Genes
1 lung combined type small cell carcinoma 32.4 SYP NCAM1
2 lung disease 32.4 TP53 NKX2-1 MIR21 GRP ENO2
3 lung squamous cell carcinoma 32.1 TUG1 TP53 PTEN PIK3CA CCAT2 B2M
4 adenosquamous carcinoma 31.8 TP53 SYP PTEN PIK3CA NKX2-1
5 melanoma 31.6 TP53 RB1 PTEN PIK3CA MALAT1 HOTAIR
6 squamous cell carcinoma 31.6 TUG1 TP73 TP53 RB1 PTEN PIK3CA
7 in situ carcinoma 31.5 TP53 PTEN PIK3CA AKT1
8 lung benign neoplasm 31.4 TP53 SYP RB1 NKX2-1 NCAM1 GRP
9 lung large cell carcinoma 31.4 SYP NKX2-1 NCAM1 CHGA
10 thyroid carcinoma 31.3 PTEN PIK3CA NKX2-1 MALAT1 HOTAIR
11 osteogenic sarcoma 31.3 TUG1 TP53 RB1 MALAT1 HOTTIP HOTAIR
12 thymoma 31.3 TP53 SYP NKX2-1 AKT1
13 adenoma 31.3 TP53 SYP PIK3CA CHGA AKT1
14 appendix adenocarcinoma 31.3 SYP CHGA
15 plasmacytoma 31.2 SYP NCAM1 B2M AKT1
16 sarcoma 31.2 TP53 RB1 PIK3CA HOTAIR AKT1
17 glioblastoma 31.2 TUG1 TP53 RB1 PTEN PIK3CA MIR21
18 papillary adenocarcinoma 31.2 TP53 NKX2-1 MIR21
19 testicular cancer 31.1 TP53 PTEN ENO2 B2M
20 diabetes mellitus 31.1 TUG1 TP53 PTEN PIK3CA MALAT1 CHGA
21 bladder cancer 31.1 TUG1 TP53 RB1 PTEN PIK3CA MIR21
22 renal cell carcinoma, nonpapillary 31.1 TUG1 TP53 PTEN PIK3CA NKX2-1 MIR21
23 esophageal cancer 31.1 TP73 TP53 RB1 PTEN PIK3CA MIR21
24 carcinoid syndrome 31.0 SYP ENO2 CHGA
25 glioma 31.0 TP53 PTEN PIK3CA MIR21 MALAT1 HOTTIP
26 leukemia, chronic lymphocytic 31.0 TP53 PTEN NCAM1 MIR21 B2M AKT1
27 carcinoid tumors, intestinal 31.0 SYP NKX2-1 ENO2 CHGA
28 retinitis pigmentosa 11 31.0 TP53 PTEN HOTAIR
29 pituitary adenoma 31.0 MALAT1 HOTAIR CHGA CCAT2
30 nasopharyngeal carcinoma 31.0 TP53 PTEN PIK3CA MIR21 MALAT1 HOTAIR
31 skin melanoma 31.0 TP53 PTEN PIK3CA B2M AKT1
32 lung cancer 31.0 TUG1 TP73 TP53 SYP RB1 PTEN
33 carcinosarcoma 30.9 TP53 PTEN PIK3CA
34 small cell carcinoma 30.9 TP53 SYP PTEN NKX2-1 NCAM1 GRP
35 kidney cancer 30.9 TP53 PTEN PIK3CA MIR21 MALAT1 HOTAIR
36 pulmonary large cell neuroendocrine carcinoma 30.9 SYP NCAM1 CHGA
37 ovarian cancer 30.9 TUG1 TP73 TP53 RB1 PTEN PIK3CA
38 papilloma 30.9 TP53 RB1 PTEN AKT1
39 thyroid gland medullary carcinoma 30.9 SYP NKX2-1 CHGA
40 brain cancer 30.9 TP73 TP53 SYP RB1 PTEN PIK3CA
41 thymic carcinoma 30.9 TP53 SYP NKX2-1 ENO2
42 pancreatic ductal adenocarcinoma 30.9 TP53 PTEN MIR21 MALAT1 HOTTIP HOTAIR
43 clear cell renal cell carcinoma 30.9 TUG1 TP53 PTEN MIR21 MALAT1 CCAT2
44 thyroid carcinoma, familial medullary 30.9 NKX2-1 MALAT1 CHGA
45 nervous system cancer 30.8 TP53 RB1 MIR21 AKT1
46 squamous cell carcinoma, head and neck 30.8 TP73 TP53 RB1 PTEN PIK3CA MIR21
47 malignant astrocytoma 30.8 TP53 PTEN CHGA AKT1
48 hydrocephalus 30.8 TP53 SYP PTEN ENO2
49 lymphoma, non-hodgkin, familial 30.8 TP53 PIK3CA NCAM1 MIR21 B2M AKT1
50 colon adenocarcinoma 30.8 TP53 PTEN PIK3CA MIR21 GRP

Graphical network of the top 20 diseases related to Small Cell Cancer of the Lung:



Diseases related to Small Cell Cancer of the Lung
Sources

Symptoms & Phenotypes for Small Cell Cancer of the Lung

About this section

Human phenotypes related to Small Cell Cancer of the Lung:

31
# Description HPO Frequency HPO Source Accession
1 neoplasm of the lung 31 HP:0100526

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
Oncology:
small-cell lung cancer

Lab:
3p23-p14 chromosome deletion in tumor

Misc:
sensitive to chemotherapy and radiotherapy

Clinical features from OMIM®:

182280 (Updated 05-Apr-2021)

MGI Mouse Phenotypes related to Small Cell Cancer of the Lung:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.77 AKT1 B2M CHGA ENO2 GRP NCAM1
2 neoplasm MP:0002006 9.76 AKT1 B2M NKX2-1 PIK3CA PTEN RB1
3 respiratory system MP:0005388 9.23 AKT1 ENO2 GRP NKX2-1 PTEN RB1
Sources

Drugs & Therapeutics for Small Cell Cancer of the Lung

About this section

Drugs for Small Cell Cancer of the Lung (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 668)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Caffeine Approved Phase 4 58-08-2 2519
2
Vinblastine Approved Phase 4 865-21-4 241903 13342
3
Durvalumab Approved, Investigational Phase 4 1428935-60-7
4
Crizotinib Approved Phase 4 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
5
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
6
Ceritinib Approved Phase 4 1032900-25-6
7
Vemurafenib Approved Phase 4 918504-65-1 42611257 23252090
8
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
10
afatinib Approved Phase 4 850140-72-6, 439081-18-2 10184653
11
Flurbiprofen Approved, Investigational Phase 4 5104-49-4 3394
12
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
13
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
14
Tyrosine Approved, Investigational, Nutraceutical Phase 4 60-18-4 6057
15
Imidacloprid Vet_approved Phase 4 105827-78-9 86418
16
Flurbiprofen axetil Investigational Phase 4 91503-79-6
17 acivicin Phase 4
18
Bilirubin Phase 4 635-65-4 5280352
19 Dermatologic Agents Phase 4
20 Endostatins Phase 4 71581480
21 Pharmaceutical Solutions Phase 4
22 Analgesics, Non-Narcotic Phase 4
23 Anti-Inflammatory Agents Phase 4
24 Analgesics Phase 4
25 Anti-Inflammatory Agents, Non-Steroidal Phase 4
26 glucocorticoids Phase 4
27
protease inhibitors Phase 4
28 HIV Protease Inhibitors Phase 4
29 Gastrointestinal Agents Phase 4
30 Antiemetics Phase 4
31 BB 1101 Phase 4
32 Cyclooxygenase Inhibitors Phase 4
33 Anesthetics Phase 4
34 Dexamethasone 21-phosphate Phase 4
35
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
36
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
37
Nabilone Approved, Investigational Phase 2, Phase 3 51022-71-0 5284592
38
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
39
Ifosfamide Approved Phase 3 3778-73-2 3690
40
Mesna Approved, Investigational Phase 3 3375-50-6 598
41
Sunitinib Approved, Investigational Phase 3 557795-19-4, 341031-54-7 5329102
42
BCG vaccine Approved, Investigational Phase 3
43
Nintedanib Approved Phase 3 656247-17-5 56843413
44
Donepezil Approved Phase 3 120014-06-4 3152
45
Disulfiram Approved Phase 2, Phase 3 97-77-8 3117
46
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
47
Epirubicin Approved Phase 3 56420-45-2 41867
48
Amifostine Approved, Investigational Phase 3 20537-88-6 2141
49
Sulindac Approved, Investigational Phase 3 38194-50-2 5352 1548887
50
Rofecoxib Approved, Investigational, Withdrawn Phase 2, Phase 3 162011-90-7 5090

Interventional clinical trials:

(show top 50) (show all 4994)
# Name Status NCT ID Phase Drugs
1 Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride in in Combination With EC/EP Unknown status NCT03890055 Phase 4 Anlotinib Hydrochloride
2 Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer: a Multi-center, Randomized, Open Label Study Unknown status NCT02348450 Phase 4 Irinotecan;Etoposide;Cisplatin
3 The Exploratory Clinical Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin (Endostar) for Local Advanced Non-small Cell Lung Cancer (NSCLC (â…¢ A / â…¢ B) ) Unknown status NCT01211002 Phase 4 radiotherapy / EP combined with recombinant human endostatin
4 A Single Center, Open Label, Multicenter Study to Determine the Safety and Efficacy of Icotinib in Combination With Whole Brain Radiation Therapy For NSCLC Patients With Brain Metastases Unknown status NCT01926171 Phase 4 Icotinib plus WBRT
5 Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research Unknown status NCT02513355 Phase 4 Changchun marina;cisplatin;Taxol;parapl
6 A Study of Endostar in Combination With Chemotherapy Followed by Endostar Maintenance Therapy in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01028729 Phase 4 Endostar;Gemcitabine-Cisplatin chemotherapy
7 Randomized, Open Label, Positive Controlled, Multicenter Trial to Evaluate Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Unknown status NCT01665417 Phase 4 Experimental;Chemotherapy;Chemotherapy
8 A Randomized,Double-blind,Placebo-Controlled,Multicenter Clinical Trail of Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT02195453 Phase 4 Yangzhengxiaoji Capsule;Placebo Capsule
9 Maintenance Gemcitabine or Best Supportive Care for the Chinese Advanced NSCLC Patients Without Progression Disease After Given Four Cycles of the Induction Chemotherapy With Gemcitabine Plus Cisplatin Unknown status NCT01336192 Phase 4 Gemcitabine;Best supportive care
10 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma: a Randomized, Open-label, Multicenter Study Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
11 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Untreated Advanced Non-small-cell Lung Cancer: a Randomized, Open-label Study Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
12 An Open Lable, Single Arm, Phase IV Study of Icotinib as First-line Treatment in Elder NSCLC Patients With EGFR Mutation Unknown status NCT01646450 Phase 4 Icotinib
13 Randomised, Controlled Study Comparing Chemotherapy Plus Intercalated EGFR-Tyrosine Kinase Inhibitors Combination Therapy With EGFR-Tyrosine Kinase Inhibitors Alone Therapy as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
14 A Phase â…£,Open,Multicenter,Single Arm Study to Evaluate the Efficacy of the Combination Conmana With Thalidomide in Patients With NSCLC(Non-Small-Cell-Lung-Cancer) Unknown status NCT02778893 Phase 4 Conmana;Thalidomide
15 A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC) Unknown status NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
16 High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation (INCREASE): a Randomized, Open-label Study Unknown status NCT02404675 Phase 4 icotinib
17 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
18 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
19 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4 Sunitinib;Erlotinib;Midazolam;Caffeine
20 A Phase IV, Multicenter, Non-randomized, Open-labeled Study to Evaluate the Efficacy of Gefitinib (IRESSA®) as a Second-line Therapy in NSCLC Patients Completed NCT00608868 Phase 4 Gefitinib
21 Clinical Study of Recombinant Human Endostatin Combined With NP Chemotherapy in the Treatment of Stage â…¢A Non Small Cell Lung Cancer Completed NCT02497118 Phase 4 Endostatin;Vinorelbine;Cisplatin
22 An Open , Single-Center, Single Arm Trial to Evaluate the Efficacy and Safety of Dose Escalation of Icotinib in Advanced NSCLC Patients After Routine Icotinib Therapy Completed NCT01465243 Phase 4 Icotinib
23 A Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemo-naive, Advanced, Non-Small-Cell Lung Cancer Patients Aged 70 Years or Older in Taiwan Completed NCT01196078 Phase 4 erlotinib [Tarceva];vinorelbine
24 Randomized Cross-over Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC. A Phase IV Study. Completed NCT01848613 Phase 4 Vinorelbine
25 Phase IV/II Open-label Study to Evaluate Prompt Response to Treatment With Cisplatin, Gemcitabine and Bevacizumab in Patients With Non-small Lung Cancer. Completed NCT02316327 Phase 4 gemcitabine, cisplatin and bevacizumab
26 A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT01066884 Phase 4 erlotinib [Tarceva]
27 Open-Label Single-Arm Phase IV Study of Pemetrexed in Taiwanese Patients With Advanced Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy Completed NCT00380718 Phase 4 pemetrexed
28 A Prospective, Multicenter, Phase-IV Clinical Trial to Assess Safety of Osimertinib in Indian Adult Patients With Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-positive Non-small Cell Lung Cancer (NSCLC). Completed NCT03853551 Phase 4 Osimertinib
29 Open-label Study of Bevacizumab (AVASTIN®) in Combination With Platinum-containing Chemotherapy as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer Completed NCT00451906 Phase 4 Platinum-based chemotherapy;Bevacizumab [Avastin]
30 A Pilot Study of the Effects of Neutropenia on Patient Reported Outcomes During Chemotherapy With or Without Neulasta® (Pegfilgrastim) in Subjects With Advanced NSCLC Completed NCT00115206 Phase 4 Neulasta® (pegfilgrastim)
31 A Dual-Cohort, Prospective, Observational Study of Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer Patients With and Without Bone Metastasis Completed NCT00099541 Phase 4 zoledronic acid
32 Phase IV Randomized Trial of Pemetrexed Followed by Docetaxel or in Reverse Sequence in Non-small-cell Lung Cancer Patients Failed Previous Chemotherapy Completed NCT01442909 Phase 4 Docetaxel and pemetrexed
33 A Multi-centre, Open-label, Phase IV, Interventional Study to Evaluate the Efficacy of Erlotinib (Tarceva®) Following 4 Cycles of Platinum-based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Experienced Disease Progression or Unacceptable Toxicity During Chemotherapy Completed NCT01230710 Phase 4 Erlotinib
34 Open Label Study of Erlotinib (Tarceva®) as Single Agent First Line Treatment of Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With Activating Epidermal Growth Factor Receptor (EGFR) Mutations Completed NCT01609543 Phase 4 erlotinib [Tarceva]
35 Safety Study of Nivolumab for Selected Advanced Malignancies in India Completed NCT03444766 Phase 4 Nivolumab
36 A Placebo-Controlled, Multicentre, Randomised, Parallel Group, Trial to Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (StageIIIB/IV) Non Small Cell Lung Cancer (NSCLC) Chinese Patients Who HaveNot Experienced Disease Progression or Unacceptable Toxicity During Front Line Standard Platinum-Based Chemotherapy Completed NCT00770588 Phase 4 Gefitinib;Placebo
37 A Multi-center Observational Clinical Study of Screening of Non-small-cell Lung Cancer With Bone Metastasis and Efficacy and Safety of Those Receiving Bisphosphonates Completed NCT00765687 Phase 4 bisphosphates
38 A Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Completed NCT01287754 Phase 4 erlotinib [Tarceva]
39 An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Cancer Completed NCT00949910 Phase 4 Erlotinib
40 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4 zometa
41 Phase IV Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin in Previously Untreated, Inoperable (Stage IIIa or IIIb) Non-small-cell Lung Cancer Completed NCT00686322 Phase 4 Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)
42 An International Expanded Access Clinical Programme With ZD1839 (IRESSATM) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC) China Amendment 1: A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa Completed NCT01000740 Phase 4
43 Multicenter Exploratory Trial of the Safety and Efficacy of Adjuvant Docetaxel and Carboplatin in Patients With Resected Non-small Cell Lung Cancer Completed NCT00883675 Phase 4 Docetaxel-Carboplatin
44 Post-marketing Clinical Trial of Induction Chemotherapy of Pemetrexed Plus Carboplatin Followed by Pemetrexed Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer Completed NCT01020786 Phase 4 Pemetrexed;Carboplatin
45 Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+) Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
46 An Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSAâ„¢) as First Line Treatment in Caucasian Patients, Who Have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer Completed NCT01203917 Phase 4 Gefitinib
47 A Single Arm Phase IV Study of Afatinib in Elderly Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Whose Tumors Have Epidermal Growth Factor Receptor (EGFR) Exon 19 Deletions or Exon 21(L858R) Substitution Mutations Completed NCT02514174 Phase 4 Afatinib
48 Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer Completed NCT03092986 Phase 4 Paclitaxel;Carboplatin;Cisplatin;Vinblastine Sulfate
49 An Open Label, Single-arm Phase IV Study to Assess the Efficacy and Safety of Afatinib as Second-line Therapy for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harbouring an EGFR Mutation (Del19 or L858R) Who Have Failed First-line Treatment With Platinum-based Chemotherapy Completed NCT02208843 Phase 4 Afatinib
50 Pembrolizumab for Metastatic Non-small Cell Lung Cancer (NSCLC) Patients Expressing PD-L1 Who Have Their Own Patient-derived Xenograft (PDX): Comparative Study of Clinical Response and In-vivo Antitumor Response Using Their Humanized CD34 PDX (Hu-CD34 PDX) Recruiting NCT03134456 Phase 4 Pembrolizumab Injection

Search NIH Clinical Center for Small Cell Cancer of the Lung

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Cisplatin
CISPLATIN PWDR
Teniposide
Topotecan
Topotecan Hydrochloride

Cochrane evidence based reviews: small cell lung carcinoma

Sources

Genetic Tests for Small Cell Cancer of the Lung

About this section

Genetic tests related to Small Cell Cancer of the Lung:

# Genetic test Affiliating Genes
1 Small Cell Lung Carcinoma 29 RB1
Sources

Anatomical Context for Small Cell Cancer of the Lung

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Small Cell Cancer of the Lung:

19
Lung

MalaCards organs/tissues related to Small Cell Cancer of the Lung:

40
Lung, Brain, Lymph Node, Bone, T Cells, Neutrophil, Endothelial
Sources

Publications for Small Cell Cancer of the Lung

About this section

Articles related to Small Cell Cancer of the Lung:

(show top 50) (show all 31107)
# Title Authors PMID Year
1
Comprehensive genomic profiles of small cell lung cancer. 57 61
26168399 2015
2
Molecular profiling of small cell lung cancer in a Japanese cohort. 6 61
24657128 2014
3
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. 57 61
22941189 2012
4
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. 61 57
22941188 2012
5
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 6
26619011 2016
6
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 6
25157968 2014
7
Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. 57
12629553 2003
8
Microsatellite alterations in plasma DNA of small cell lung cancer patients. 57
8782463 1996
9
Definition of a tumor suppressor locus within human chromosome 3p21-p22. 57
1438292 1992
10
Three distinct regions involved in 3p deletion in human lung cancer. 57
1347916 1992
11
An unusually proximal deletion on the short arm of chromosome 3 in a patient with small cell lung cancer. 57
1672284 1991
12
Oncogenic point mutations in the human retinoblastoma gene: their application to genetic counseling. 6
2594029 1989
13
Loss of heterozygosity in a gene coding for a thyroid hormone receptor in lung cancers. 57
2536219 1989
14
Localization of human ERBA2 to the 3p22----3p24.1 region of chromosome 3 and variable deletion in small cell lung cancer. 57
2848257 1988
15
Restriction fragment length polymorphism studies show consistent loss of chromosome 3p alleles in small cell lung cancer patients' tumors. 57
2900253 1988
16
Molecular genetics of lung cancer. 57
3289123 1988
17
Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. 57
2825033 1987
18
Loss of heterozygosity on chromosomes 3, 13, and 17 in small-cell carcinoma and on chromosome 3 in adenocarcinoma of the lung. 57
2892196 1987
19
Molecular analysis of the short arm of chromosome 3 in small-cell and non-small-cell carcinoma of the lung. 57
2821398 1987
20
Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. 57
2821400 1987
21
Loss of heterozygosity for a chromosome 3 sequence presumably at 3p21 in small cell lung cancer. 57
2885082 1987
22
Small cell lung cancer cell line derived from a primary tumor with a characteristic deletion of 3p. 57
3030544 1987
23
Characterization of three new variant type cell lines derived from small cell carcinoma of the lung. 57
2998591 1985
24
A 3p deletion in small cell lung carcinoma. 57
2982478 1985
25
Small cell carcinoma of the lung: macrophage-specific antigens suggest hemopoietic stem cell origin. 57
6089338 1984
26
A unique cell-surface protein phenotype distinguishes human small-cell from non-small-cell lung cancer. 57
6289311 1982
27
A nonrandom chromosomal abnormality, del 3p(14-23), in human small cell lung cancer (SCLC). 57
6286098 1982
28
Human lung small-cell carcinoma contains bombesin. 57
6285381 1982
29
Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23). 57
6274023 1982
30
Levels of creatine kinase and its BB isoenzyme in lung cancer specimens and cultures. 57
6265067 1981
31
Neuron-specific enolase is produced by neuroendocrine tumours. 57
6111674 1981
32
Cytogenetic effects of cigarette smoke condensates in vitro and in vivo. 57
7333590 1981
33
MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. 47
20508945 2011
34
Evaluation of 7q31 region improves the accuracy of EGFR FISH assay in non small cell lung cancer. 61 54
19889201 2009
35
Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. 54 61
19887547 2009
36
Epidermal growth factor receptor mutations in small cell lung cancer. 61 54
18829487 2008
37
Inhibition of fibroblast growth factor 2-induced apoptosis involves survivin expression, protein kinase C alpha activation and subcellular translocation of Smac in human small cell lung cancer cells. 54 61
18401527 2008
38
Neuron specific enolase tissue expression as a prognostic factor in advanced non small cell lung cancer. 54 61
18404793 2008
39
Prognostic and predictive value of vascular endothelial growth factor and its soluble receptors, VEGFR-1 and VEGFR-2 levels in the sera of small cell lung cancer patients. 54 61
18317954 2008
40
[Role of the cut-off value of serum neuron-specific enolase in differentiating small cell lung cancer from non-small cell lung cancer]. 54 61
16793621 2006
41
Mechanisms for the apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies: roles of anoikis. 54 61
15923178 2005
42
Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. 61 54
15205342 2004
43
A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer. 54 61
9331137 1997
44
Discriminant analysis on small cell lung cancer and non-small cell lung cancer by means of NSE and CYFRA-21.1. 61 54
7589398 1995
45
Enhanced expression of HLA-A,B,C and inducibility of TAP-1, TAP-2, and HLA-A,B,C by interferon-gamma in a multidrug-resistant small cell lung cancer line. 54 61
8061113 1994
46
Human aminoacylase-1. Cloning, sequence, and expression analysis of a chromosome 3p21 gene inactivated in small cell lung cancer. 54 61
8394326 1993
47
Human granulocyte colony-stimulating factor: biologic activities and receptor characterization on hematopoietic cells and small cell lung cancer cell lines. 61 54
1689190 1990
48
Targeted next-generation sequencing for cancer-associated gene mutation and copy number detection in 206 patients with non-small-cell lung cancer. 61
33629637 2021
49
Circular RNA circ_0001287 inhibits the proliferation, metastasis, and radiosensitivity of non-small cell lung cancer cells by sponging microRNA miR-21 and up-regulating phosphatase and tensin homolog expression. 61
33467964 2021
50
Celastrol acts synergistically with afatinib to suppress non-small cell lung cancer cell proliferation by inducing paraptosis. 61
33230821 2021
Sources

Variations for Small Cell Cancer of the Lung

About this section

ClinVar genetic disease variations for Small Cell Cancer of the Lung:

6 (show top 50) (show all 106)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 RB1 NM_000321.3(RB1):c.1215+1G>A SNV Pathogenic 126832 rs587776783 GRCh37: 13:48947629-48947629
GRCh38: 13:48373493-48373493
2 overlap with 54 genes t(2;2)(p23;p21)(hg19 chr2:g.42552694::ochr2:g.29446394) Inversion Pathogenic 487484 GRCh37: 2:29446394-42552694
GRCh38:
3 RB1 NM_000321.2(RB1):c.2242G>T (p.Glu748Ter) SNV Pathogenic 13078 rs121913297 GRCh37: 13:49039164-49039164
GRCh38: 13:48465028-48465028
4 RB1 NM_000321.3(RB1):c.1981C>T SNV Pathogenic 13087 rs137853294 GRCh37: 13:49033844-49033844
GRCh38: 13:48459708-48459708
5 RB1 NM_000321.2(RB1):c.2117G>T (p.Cys706Phe) SNV Likely pathogenic 376330 rs121913295 GRCh37: 13:49037877-49037877
GRCh38: 13:48463741-48463741
6 TP53 NM_000546.5(TP53):c.746G>T (p.Arg249Met) SNV Likely pathogenic 376653 rs587782329 GRCh37: 17:7577535-7577535
GRCh38: 17:7674217-7674217
7 TP53 NM_000546.5(TP53):c.518T>G (p.Val173Gly) SNV Likely pathogenic 376016 rs1057519747 GRCh37: 17:7578412-7578412
GRCh38: 17:7675094-7675094
8 TP53 NM_000546.5(TP53):c.373A>C (p.Thr125Pro) SNV Likely pathogenic 376666 rs1057520003 GRCh37: 17:7579314-7579314
GRCh38: 17:7675996-7675996
9 TP53 NM_000546.5(TP53):c.856G>C (p.Glu286Gln) SNV Likely pathogenic 376591 rs786201059 GRCh37: 17:7577082-7577082
GRCh38: 17:7673764-7673764
10 TP53 NM_000546.5(TP53):c.746G>C (p.Arg249Thr) SNV Likely pathogenic 376015 rs587782329 GRCh37: 17:7577535-7577535
GRCh38: 17:7674217-7674217
11 TP53 NM_000546.5(TP53):c.536A>G (p.His179Arg) SNV Likely pathogenic 376606 rs1057519991 GRCh37: 17:7578394-7578394
GRCh38: 17:7675076-7675076
12 TP53 NM_000546.5(TP53):c.658T>A (p.Tyr220Asn) SNV Likely pathogenic 376688 rs530941076 GRCh37: 17:7578191-7578191
GRCh38: 17:7674873-7674873
13 PIK3CA NM_006218.4(PIK3CA):c.1624G>A (p.Glu542Lys) SNV Likely pathogenic 31944 rs121913273 GRCh37: 3:178936082-178936082
GRCh38: 3:179218294-179218294
14 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys) SNV Likely pathogenic 13655 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
15 TP53 NM_000546.5(TP53):c.487T>C (p.Tyr163His) SNV Likely pathogenic 376680 rs786203436 GRCh37: 17:7578443-7578443
GRCh38: 17:7675125-7675125
16 TP53 NM_000546.5(TP53):c.700T>A (p.Tyr234Asn) SNV Likely pathogenic 376692 rs864622237 GRCh37: 17:7577581-7577581
GRCh38: 17:7674263-7674263
17 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala) SNV Likely pathogenic 13659 rs121913274 GRCh37: 3:178936092-178936092
GRCh38: 3:179218304-179218304
18 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp) SNV Likely pathogenic 12347 rs121912651 GRCh37: 17:7577539-7577539
GRCh38: 17:7674221-7674221
19 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln) SNV Likely pathogenic 12356 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220
20 TP53 NM_000546.6(TP53):c.820G>T SNV Likely pathogenic 376674 rs1057520005 GRCh37: 17:7577118-7577118
GRCh38: 17:7673800-7673800
21 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His) SNV Likely pathogenic 12366 rs28934576 GRCh37: 17:7577120-7577120
GRCh38: 17:7673802-7673802
22 PTEN NM_000314.7(PTEN):c.389G>A (p.Arg130Gln) SNV Likely pathogenic 7829 rs121909229 GRCh37: 10:89692905-89692905
GRCh38: 10:87933148-87933148
23 TP53 NM_000546.5(TP53):c.517G>A (p.Val173Met) SNV Likely pathogenic 233951 rs876660754 GRCh37: 17:7578413-7578413
GRCh38: 17:7675095-7675095
24 TP53 NM_000546.5(TP53):c.701A>C (p.Tyr234Ser) SNV Likely pathogenic 376690 rs587780073 GRCh37: 17:7577580-7577580
GRCh38: 17:7674262-7674262
25 TP53 NM_000546.6(TP53):c.659A>G (p.Tyr220Cys) SNV Likely pathogenic 127819 rs121912666 GRCh37: 17:7578190-7578190
GRCh38: 17:7674872-7674872
26 TP53 NM_000546.5(TP53):c.700T>C (p.Tyr234His) SNV Likely pathogenic 376691 rs864622237 GRCh37: 17:7577581-7577581
GRCh38: 17:7674263-7674263
27 TP53 NM_000546.5(TP53):c.700T>G (p.Tyr234Asp) SNV Likely pathogenic 219759 rs864622237 GRCh37: 17:7577581-7577581
GRCh38: 17:7674263-7674263
28 TP53 NM_000546.5(TP53):c.701A>G (p.Tyr234Cys) SNV Likely pathogenic 127820 rs587780073 GRCh37: 17:7577580-7577580
GRCh38: 17:7674262-7674262
29 TP53 NM_000546.5(TP53):c.487T>G (p.Tyr163Asp) SNV Likely pathogenic 187052 rs786203436 GRCh37: 17:7578443-7578443
GRCh38: 17:7675125-7675125
30 TP53 NM_000546.5(TP53):c.839G>C (p.Arg280Thr) SNV Likely pathogenic 12368 rs121912660 GRCh37: 17:7577099-7577099
GRCh38: 17:7673781-7673781
31 TP53 NM_000546.5(TP53):c.643A>G (p.Ser215Gly) SNV Likely pathogenic 265337 rs886039484 GRCh37: 17:7578206-7578206
GRCh38: 17:7674888-7674888
32 TP53 NM_000546.5(TP53):c.838A>G (p.Arg280Gly) SNV Likely pathogenic 376658 rs753660142 GRCh37: 17:7577100-7577100
GRCh38: 17:7673782-7673782
33 PIK3CA NM_006218.4(PIK3CA):c.1624G>C (p.Glu542Gln) SNV Likely pathogenic 376244 rs121913273 GRCh37: 3:178936082-178936082
GRCh38: 3:179218294-179218294
34 TP53 NM_000546.5(TP53):c.857A>G (p.Glu286Gly) SNV Likely pathogenic 376590 rs1057519985 GRCh37: 17:7577081-7577081
GRCh38: 17:7673763-7673763
35 TP53 NM_000546.5(TP53):c.587G>C (p.Arg196Pro) SNV Likely pathogenic 231165 rs483352697 GRCh37: 17:7578262-7578262
GRCh38: 17:7674944-7674944
36 TP53 NM_000546.5(TP53):c.535C>G (p.His179Asp) SNV Likely pathogenic 376610 rs587780070 GRCh37: 17:7578395-7578395
GRCh38: 17:7675077-7675077
37 TP53 NM_000546.5(TP53):c.644G>T (p.Ser215Ile) SNV Likely pathogenic 376660 rs587782177 GRCh37: 17:7578205-7578205
GRCh38: 17:7674887-7674887
38 TP53 NM_000546.5(TP53):c.518T>A (p.Val173Glu) SNV Likely pathogenic 376669 rs1057519747 GRCh37: 17:7578412-7578412
GRCh38: 17:7675094-7675094
39 TP53 NM_000546.5(TP53):c.578A>T (p.His193Leu) SNV Likely pathogenic 185822 rs786201838 GRCh37: 17:7578271-7578271
GRCh38: 17:7674953-7674953
40 PIK3CA NM_006218.4(PIK3CA):c.1625A>C (p.Glu542Ala) SNV Likely pathogenic 376473 rs1057519927 GRCh37: 3:178936083-178936083
GRCh38: 3:179218295-179218295
41 AKT1 NM_005163.2(AKT1):c.49G>A (p.Glu17Lys) SNV Likely pathogenic 13983 rs121434592 GRCh37: 14:105246551-105246551
GRCh38: 14:104780214-104780214
42 TP53 NM_000546.5(TP53):c.535C>A (p.His179Asn) SNV Likely pathogenic 376609 rs587780070 GRCh37: 17:7578395-7578395
GRCh38: 17:7675077-7675077
43 TP53 NM_000546.5(TP53):c.731G>A (p.Gly244Asp) SNV Likely pathogenic 372785 rs985033810 GRCh37: 17:7577550-7577550
GRCh38: 17:7674232-7674232
44 TP53 NM_000546.5(TP53):c.578A>C (p.His193Pro) SNV Likely pathogenic 376612 rs786201838 GRCh37: 17:7578271-7578271
GRCh38: 17:7674953-7674953
45 TP53 NM_000546.5(TP53):c.535C>T (p.His179Tyr) SNV Likely pathogenic 127815 rs587780070 GRCh37: 17:7578395-7578395
GRCh38: 17:7675077-7675077
46 PTEN NM_000314.8(PTEN):c.389G>T SNV Likely pathogenic 376509 rs121909229 GRCh37: 10:89692905-89692905
GRCh38: 10:87933148-87933148
47 TP53 NM_000546.5(TP53):c.374C>G (p.Thr125Arg) SNV Likely pathogenic 376667 rs786201057 GRCh37: 17:7579313-7579313
GRCh38: 17:7675995-7675995
48 TP53 NM_000546.5(TP53):c.488A>G (p.Tyr163Cys) SNV Likely pathogenic 127814 rs148924904 GRCh37: 17:7578442-7578442
GRCh38: 17:7675124-7675124
49 TP53 NM_000546.5(TP53):c.730G>A (p.Gly244Ser) SNV Likely pathogenic 376600 rs1057519989 GRCh37: 17:7577551-7577551
GRCh38: 17:7674233-7674233
50 TP53 NM_000546.5(TP53):c.821T>A (p.Val274Asp) SNV Likely pathogenic 376675 rs1057520006 GRCh37: 17:7577117-7577117
GRCh38: 17:7673799-7673799

Copy number variations for Small Cell Cancer of the Lung from CNVD:

7 (show top 50) (show all 515)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 15909 1 120235683 147296355 Substitutions and indels small cell lung cancer
2 18774 1 147306435 159745095 Substitutions and indels small cell lung cancer
3 21590 1 159753915 159864147 Substitutions and indels small cell lung cancer
4 21631 1 159879159 167481135 Substitutions and indels small cell lung cancer
5 22562 1 167488767 167515635 Substitutions and indels small cell lung cancer
6 22575 1 167524383 182844003 Substitutions and indels small cell lung cancer
7 22643 1 16801095 16840107 Substitutions and indels small cell lung cancer
8 22724 1 16861959 29150031 Substitutions and indels small cell lung cancer
9 24621 1 182849019 182888703 Substitutions and indels small cell lung cancer
10 24623 1 182893695 194979795 Substitutions and indels small cell lung cancer
11 25853 1 194993223 195074031 Substitutions and indels small cell lung cancer
12 25942 1 195088143 205083387 Substitutions and indels small cell lung cancer
13 27160 1 205088907 205109547 Substitutions and indels small cell lung cancer
14 27163 1 205114395 208124379 Substitutions and indels small cell lung cancer
15 27411 1 208129227 208155879 Substitutions and indels small cell lung cancer
16 27424 1 208162923 222138663 Substitutions and indels small cell lung cancer
17 28412 1 222150063 222281979 Substitutions and indels small cell lung cancer
18 28435 1 222297471 247249719 Substitutions and indels small cell lung cancer
19 31650 1 29155527 30043083 Substitutions and indels small cell lung cancer
20 31718 1 30048807 41173191 Substitutions and indels small cell lung cancer
21 32828 1 39746 16783059 Substitutions and indels small cell lung cancer
22 33011 1 41174800 41175800 Intrachromosomal rearrangement small cell lung cancer
23 33013 1 41178543 42371163 Substitutions and indels small cell lung cancer
24 33099 1 42374208 42375208 Intrachromosomal rearrangement small cell lung cancer
25 33100 1 42376011 42579327 Substitutions and indels small cell lung cancer
26 33116 1 42583395 42584395 Intrachromosomal rearrangement small cell lung cancer
27 33117 1 42584427 44255643 Substitutions and indels small cell lung cancer
28 33294 1 44259752 44260752 Intrachromosomal rearrangement small cell lung cancer
29 33295 1 44260511 44261511 Intrachromosomal rearrangement small cell lung cancer
30 33296 1 44260527 44275323 Substitutions and indels small cell lung cancer
31 33300 1 44279330 44280330 Intrachromosomal rearrangement small cell lung cancer
32 33301 1 44279742 44280742 Intrachromosomal rearrangement small cell lung cancer
33 33302 1 44280303 48578211 Substitutions and indels small cell lung cancer
34 33819 1 48580747 48581747 Intrachromosomal rearrangement small cell lung cancer
35 33821 1 48583227 51275739 Substitutions and indels small cell lung cancer
36 33980 1 51279608 51280608 Intrachromosomal rearrangement small cell lung cancer
37 33981 1 51281079 54467547 Substitutions and indels small cell lung cancer
38 34296 1 54469360 54470360 Intrachromosomal rearrangement small cell lung cancer
39 34297 1 54473247 54557103 Substitutions and indels small cell lung cancer
40 34301 1 54561497 54562497 Intrachromosomal rearrangement small cell lung cancer
41 34302 1 54562083 54649251 Substitutions and indels small cell lung cancer
42 34322 1 54652634 54653634 Intrachromosomal rearrangement small cell lung cancer
43 34323 1 54654159 57627915 Substitutions and indels small cell lung cancer
44 34908 1 57632775 57657135 Substitutions and indels small cell lung cancer
45 34910 1 57661947 72536187 Substitutions and indels small cell lung cancer
46 36221 1 72541191 72583059 Substitutions and indels small cell lung cancer
47 36257 1 72587919 85749039 Substitutions and indels small cell lung cancer
48 37122 1 85755495 85774959 Substitutions and indels small cell lung cancer
49 37129 1 85779879 120230763 Substitutions and indels small cell lung cancer
50 41421 10 17866791 18173655 Substitutions and indels small cell lung cancer
Sources

Expression for Small Cell Cancer of the Lung

About this section
Search GEO for disease gene expression data for Small Cell Cancer of the Lung.
Sources

Pathways for Small Cell Cancer of the Lung

About this section

Pathways related to Small Cell Cancer of the Lung according to KEGG:

36
# Name Kegg Source Accession
1 Small cell lung cancer hsa05222
2 MicroRNAs in cancer hsa05206

Pathways related to Small Cell Cancer of the Lung according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Pathways in cancer 36
12.77 TP53 RB1 PTEN PIK3CA AKT1
2
Gastric cancer 36
Show member pathways
 12.69 TP53 RB1 PTEN PIK3CA AKT1
3
Measles 36
Show member pathways
 12.66 TP73 TP53 RB1 PIK3CA B2M AKT1
4
Development HGF signaling pathway 23
Show member pathways
 12.62 TP73 TP53 PTEN PIK3CA AKT1
5
Glioma 36
Show member pathways
 12.58 TP53 RB1 PTEN PIK3CA AKT1
6
Development IGF-1 receptor signaling 23
Show member pathways
 12.32 TP53 PTEN PIK3CA AKT1
7
DNA Damage Response 1
Show member pathways
 12.3 TP73 TP53 RB1 PTEN
8
Translation Non-genomic (rapid) action of Androgen Receptor 23
Show member pathways
 12.23 TP53 PTEN PIK3CA AKT1
9
Proteoglycans in cancer 36
12.21 TP53 PIK3CA MIR21 AKT1
10
p53 Signaling 63
Show member pathways
 12.15 TP53 RB1 PTEN AKT1
11
MAPK Signaling: Mitogen Stimulation Pathway 64
Show member pathways
 12.12 TP53 RB1 PTEN PIK3CA AKT1
12
Integrated Breast Cancer Pathway 1
12.04 TP53 RB1 PTEN AKT1
13
Cellular senescence (KEGG) 36
11.96 TP53 RB1 PTEN PIK3CA AKT1
14
Direct p53 effectors 1
11.95 TP73 TP53 RB1 PTEN
15
Sphingolipid signaling pathway 36
11.89 TP53 PTEN PIK3CA AKT1
16
Glioblastoma Multiforme 63
11.8 TP53 RB1 PTEN AKT1
17
Human T-cell leukemia virus 1 infection 36
11.77 TP53 RB1 PTEN PIK3CA B2M AKT1
18
TP53 Regulates Metabolic Genes 65
11.75 TP53 PTEN AKT1
19
Platinum drug resistance 36
11.67 TP53 PIK3CA AKT1
20
Human Thyroid Stimulating Hormone (TSH) signaling pathway 1
11.63 RB1 PIK3CA AKT1
21
p75(NTR)-mediated signaling 1
Show member pathways
 11.61 TP53 PIK3CA AKT1
22
DNA Damage Response (only ATM dependent) 1
11.61 TP73 TP53 PTEN PIK3CA AKT1
23
Central carbon metabolism in cancer 36
11.58 TP53 PTEN PIK3CA AKT1
24
Pathways Affected in Adenoid Cystic Carcinoma 1
11.52 TP53 PTEN PIK3CA AKT1
25
PDGFR-beta signaling pathway 1
11.48 PTEN PIK3CA AKT1
26
FGF signaling pathway 1
11.41 PIK3CA NCAM1 AKT1
27
Copper homeostasis 1
11.36 TP53 PTEN PIK3CA AKT1
28
Integrated Cancer Pathway 1
11.22 TP53 RB1 PTEN AKT1
29
PI3K-AKT-mTOR signaling pathway and therapeutic opportunities 1
11.15 PTEN PIK3CA AKT1
30
Small cell lung cancer 36
10.98 TP53 RB1 PTEN PIK3CA AKT1
31
LncRNA-mediated mechanisms of therapeutic resistance 1
10.73 TP53 HOTAIR
Sources

GO Terms for Small Cell Cancer of the Lung

About this section

Biological processes related to Small Cell Cancer of the Lung according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.92 TP53 PTEN NKX2-1 MIR21 AKT1
2 negative regulation of cell proliferation GO:0008285 9.85 TP73 TP53 RB1 PTEN MIR21
3 positive regulation of apoptotic process GO:0043065 9.77 TP73 TP53 PTEN MIR21 AKT1
4 interferon-gamma-mediated signaling pathway GO:0060333 9.65 TP53 NCAM1 B2M
5 negative regulation of epithelial cell proliferation GO:0050680 9.61 RB1 PTEN B2M
6 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.58 RB1 PTEN MIR21
7 anoikis GO:0043276 9.51 PIK3CA AKT1
8 negative regulation of cell size GO:0045792 9.49 PTEN AKT1
9 protein kinase B signaling GO:0043491 9.33 PTEN PIK3CA AKT1
10 positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathway GO:1900738 9.32 GRP CHGA
11 cellular response to decreased oxygen levels GO:0036294 9.26 PTEN AKT1
12 phosphatidylinositol 3-kinase signaling GO:0014065 9.13 PTEN PIK3CA AKT1
13 cellular response to hypoxia GO:0071456 8.92 TP53 PTEN MALAT1 AKT1

Molecular functions related to Small Cell Cancer of the Lung according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.56 TP73 TP53 SYP RB1 PTEN NCAM1
2 MDM2/MDM4 family protein binding GO:0097371 9.16 TP73 TP53
3 enzyme binding GO:0019899 9.02 TP53 RB1 PTEN NKX2-1 AKT1
Sources

Sources for Small Cell Cancer of the Lung

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....